Skip to main content
. Author manuscript; available in PMC: 2023 Sep 1.
Published in final edited form as: Contemp Clin Trials. 2022 Aug 24;120:106895. doi: 10.1016/j.cct.2022.106895

Table 1.

Optimization potential score (OPS).

Points
None Low Dose Targeted Dose
ACE/ARB/ARNI 0 1 2
Beta Blocker 0 1 2
MRA 0 1 2
ARNI 0 1 2
SGLT2i 0 – 2

ACE Angiotensin-converting enzyme inhibitors, ARB angiotensin receptor blocker, ARNI, Angiotensin Receptor-Neprilysin Inhibitor, MRA mineralocorticoid receptor antagonist, SGLT2i sodium-glucose cotransporter-2 inhibitors.